Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats

J Pharmacol Exp Ther. 1996 Jan;276(1):56-64.

Abstract

The present study evaluated the modulatory role of central corticotropin-releasing factor (CRF) systems in the mediation of the effects of acute exposure to the brain cannabinoid receptor agonist HU-210 [3-(1,1-dimethylheptyl)-(-)-11-hydroxy-delta 8-tetrahydrocannabinol] on defensive withdrawal behavior in male rats. The apparatus used for the defensive withdrawal test consisted of a small chamber, set on one side of a one-square meter open field. The actions of the potent CRF antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF (D-Phe CRF12-41) were examined on defensive behavior under both novel and familiar conditions. The acute i.c.v. administration of D-Phe CRF12-41 (0.2-5 micrograms/injection) antagonized the defensive behavior response to stressing conditions such as novelty or swim stress in field-habituated animals. The acute i.p. administration of HU-210 (4, 20 and 100 micrograms/kg) produced a clear dose-dependent stress-like effects in field-habituated animals, as reflected in the HU-210-induced increase in both the emergence latency and the mean time spent in the small chamber. The i.c.v. administration of 5 micrograms of D-Phe CRF12-41, 5 min before the administration of the cannabinoid prevented the stressing actions of HU-210 (20 micrograms/kg, but not 100 micrograms/kg). Acute administration of HU-210 also induced a dose-dependent increase in plasma corticosterone levels which was not antagonized by pretreatment with 5 micrograms of D-Phe CRF12-41. The present study suggests a role of central CRF systems in the mediation of the anxiogenic effects of brain cannabinoid receptor agonists. This finding is consistent with a direct hypothalamic effect of cannabinoids on the activation of the pituitary-adrenal axis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Anxiety / drug therapy*
  • Behavior, Animal / drug effects*
  • Corticosterone / blood
  • Corticotropin-Releasing Hormone / analogs & derivatives*
  • Corticotropin-Releasing Hormone / antagonists & inhibitors*
  • Corticotropin-Releasing Hormone / metabolism
  • Corticotropin-Releasing Hormone / pharmacology
  • Defense Mechanisms*
  • Dronabinol / analogs & derivatives*
  • Dronabinol / pharmacology
  • Drug Interactions
  • Drug Synergism
  • Male
  • Neuroprotective Agents / pharmacology*
  • Peptide Fragments / pharmacology*
  • Rats
  • Rats, Wistar
  • Receptors, Cannabinoid
  • Receptors, Drug / agonists*
  • Stress, Physiological / physiopathology
  • Swimming

Substances

  • H-R corticotropin-releasing factor (12-41), Phe(12)-Nle(21,38), C(alpha-MeLeu(37))-
  • Neuroprotective Agents
  • Peptide Fragments
  • Receptors, Cannabinoid
  • Receptors, Drug
  • phenylalanyl corticotropin-releasing factor (12-41)
  • Dronabinol
  • Corticotropin-Releasing Hormone
  • HU 211
  • Corticosterone